Literature DB >> 18767195

Combinatorial, selective and reversible control of gene expression using oligodeoxynucleotides in a cell-free protein synthesis system.

Jung-Won Keum1, Jin-Ho Ahn, Taek Jin Kang, Dong-Myung Kim.   

Abstract

Herein we describe the methods for selective and reversible regulation of gene expression using antisense oligodeoxynucleotides (ODNs) in a cell-free protein synthesis system programmed with multiple DNAs. Either a complete shut down or controlled level of gene expression was attained through the antisense ODN-mediated regulation of mRNA stability in the reaction mixture. In addition to the primary control of gene expression, we also demonstrate that the inhibition of protein synthesis can be reversed by using an anti-antisense ODN sequence that strips the antisense ODN off the target sequence of mRNA. As a result, sequential additions of the antisense and anti-antisense ODNs enabled the stop-and-go expression of protein molecules. Through the on-demand regulation of gene expression, presented results will provide a versatile platform for the analysis and understanding of the complicated networks of biological components.

Mesh:

Substances:

Year:  2009        PMID: 18767195     DOI: 10.1002/bit.22081

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  3 in total

1.  Flexible programming of cell-free protein synthesis using magnetic bead-immobilized plasmids.

Authors:  Ka-Young Lee; Kyung-Ho Lee; Ji-Woong Park; Dong-Myung Kim
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

2.  A molecular nanodevice for targeted degradation of mRNA during protein synthesis.

Authors:  Kyung-Ho Lee; Seung-Eui Min; Haseong Kim; Seung-Goo Lee; Dong-Myung Kim
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

3.  Differential network analysis reveals genetic effects on catalepsy modules.

Authors:  Ovidiu D Iancu; Denesa Oberbeck; Priscila Darakjian; Sunita Kawane; Jason Erk; Shannon McWeeney; Robert Hitzemann
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.